Pathios Therapeutics is pioneering a novel approach to cancer treatment by targeting the acid-sensing G protein-coupled receptor (GPCR), GPR65. This receptor is uniquely expressed on immune cells and plays a critical role in the immunosuppressive environment of tumors, particularly in solid cancers where the tumor microenvironment (TME) is often acidic. Pathios has identified that the activation of GPR65 by low pH conditions leads to a detrimental alteration in immune cell function, promoting a pro-tumorigenic phenotype that undermines the efficacy of existing immunotherapies. By inhibiting GPR65, Pathios aims to reverse these immunosuppressive effects, thereby enhancing the anti-tumor immune response and potentially transforming treatment outcomes for patients with advanced solid tumors.

The company's lead asset, PTT-4256, is an orally bioavailable and highly selective GPR65 inhibitor that has shown promising preclinical results, including anti-tumor activity in mouse models. Currently, PTT-4256 is undergoing evaluation in a Phase 1/2 clinical trial, RAISIC-1, which aims to assess its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors. Pathios' innovative approach is supported by human genetic analysis indicating that reduced GPR65 function correlates with improved survival across various cancer types. This unique focus on the underlying biology of immune cell dysfunction in the TME positions Pathios Therapeutics at the forefront of developing first-in-class therapies that could significantly impact cancer treatment.

United Kingdom

Pathios Therapeutics is a clinical-stage oncology and immunology company that targets the acid-sensing GPCR, GPR65. The company is focused on the development of first-in-class therapies for cancer.

Pathios Therapeutics

Company Details